Division of Gastroenterology and Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, California.
Liver Failure Group, Institute for Liver and Digestive Health, UCL Medical School, London, UK.
Gastroenterology. 2019 Apr;156(5):1381-1391.e3. doi: 10.1053/j.gastro.2018.12.007. Epub 2018 Dec 18.
BACKGROUND & AIMS: Liver transplantation for patients with acute-on-chronic liver failure (ACLF) with 3 or more failing organs (ACLF-3) is controversial. We compared liver waitlist mortality or removal according to model for end-stage liver disease (MELD) score vs ACLF category. We also studied factors associated with reduced odds of survival for 1 year after liver transplantation in patients with ACLF-3.
We analyzed data from the United Network for Organ Sharing (UNOS) from 2005 through 2016. We identified patients who were on the waitlist (100,594) and those who received liver transplants (50,552). Patients with ACLF were identified based on the European Association for the Study of the Liver-chronic liver failure criteria. Outcomes were evaluated with competing risks regression, Kaplan-Meier analysis, and Cox proportional hazards regression.
Patients with ACLF-3 were more likely to die or be removed from the waitlist, regardless of MELD-sodium (MELD-Na) score, compared with the other ACLF groups; the proportion was greatest for patients with an ACLF-3 score and MELD-Na score below 25 (43.8% at 28 days). Mechanical ventilation at liver transplantation (hazard ratio [HR] 1.49; 95% confidence interval [CI] 1.22-1.84), donor risk index above 1.7 (HR 1.22; 95% CI 1.09-1.35), and liver transplantation within 30 days of listing (HR 0.89; 95% CI 0.81-0.98) were independently associated with survival for 1 year after liver transplantation CONCLUSIONS: In an analysis of data from the UNOS registry, we found high mortality among patients with ACLF-3 on the liver transplant waitlist, even among those with lower MELD-Na scores. So, certain patients with ACLF-3 have poor outcomes regardless of MELD-Na score. Liver transplantation increases odds of survival for these patients, particularly if performed within 30 days of placement on the waitlist. Mechanical ventilation at liver transplantation and use of marginal organs were associated with increased risk of death.
对于合并 3 个或更多衰竭器官的慢加急性肝衰竭(ACLF)患者行肝移植尚存争议。我们比较了根据终末期肝病模型(MELD)评分与 ACLF 分类的肝移植候补者死亡率或移除率。我们还研究了合并 3 个衰竭器官的 ACLF 患者肝移植后 1 年生存率降低的相关因素。
我们分析了 2005 年至 2016 年期间美国器官共享联合网络(UNOS)的数据。我们确定了候补者(100594 例)和接受肝移植者(50552 例)。根据欧洲肝脏研究协会-慢性肝衰竭标准确定 ACLF 患者。采用竞争风险回归、Kaplan-Meier 分析和 Cox 比例风险回归评估结局。
无论 MELD-钠(MELD-Na)评分如何,与其他 ACLF 组相比,合并 3 个衰竭器官的 ACLF 患者更有可能在等待期间死亡或被移除;MELD-Na 评分低于 25 且合并 ACLF-3 评分的患者比例最大(28 天内为 43.8%)。肝移植时使用机械通气(风险比 [HR] 1.49;95%置信区间 [CI] 1.22-1.84)、供体风险指数大于 1.7(HR 1.22;95% CI 1.09-1.35)和在列入候补名单后 30 天内进行肝移植(HR 0.89;95% CI 0.81-0.98)与肝移植后 1 年生存率独立相关。
在对 UNOS 登记处数据的分析中,我们发现即使在 MELD-Na 评分较低的情况下,肝移植候补者中合并 3 个衰竭器官的 ACLF 患者死亡率也很高。因此,某些合并 3 个衰竭器官的 ACLF 患者无论 MELD-Na 评分如何,预后均较差。肝移植可增加这些患者的生存率,特别是在列入候补名单后 30 天内进行移植。肝移植时使用机械通气和使用边缘供体与死亡风险增加相关。